Sereejav, Enkhbold
Loading...
Товч нэр
Sereejav, Enkhbold
Бүтэн нэр
Sereejav Enkhbold
Латин нэр
Sereejav Enkhbold
Албан тушаал
Судлаач
ORCID
7 results
Now showing 1 - 7 of 7
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Antibody Responses to mRNA Versus Non-mRNA COVID Vaccines Among Mongolian Population(Elsevier BV, 2022); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Distribution of 10-year cardiovascular disease risk levels in Mongolia: results from nation-wide health screening programINTRODUCTION: The Mongolian government recently initiated the first nationwide health screening program to assess the health status of the entire population using age-group specific health risk assessments related to the major noncommunicable diseases and behavioral risk factors. Based on data collected from nationwide health screening program, we estimated the distribution of 10-year cardiovascular disease (CVD) risks in the general population by using the risk prediction model recently published by the World Health Organization (WHO). METHODS: A representative sample of 35,769 adults aged between 40 and 80 years old participated in nationwide health screening program, which covered all 21 Mongolian provinces and 9 districts in the capital city Ulaanbaatar. Data used in the present study were obtained from the first wave of the screening program, which was held throughout Mongolia between May 2022 and February 2023. To assess the four categories of CVD risk and determine the 10-year risk of a fatal/non-fatal event, we used the WHO CVD risk 2019 laboratory-based cardiovascular disease risk charts. The following key risk factors were used to assess the 10-year CVD risk: gender, age, location, smoking status, body mass index, total cholesterol level, history of diabetes, fasting glucose level, and blood pressure level. The 10-year risk for CVD was divided into four groups: low risk (< 10%), mild risk (10 to 20%), moderate risk (20 to 30%), and high risk (> 30%). RESULTS: Total of 35,769 adults aged between 40 and 80 years old participated in the nationwide health screening program. The mean age of the participants in the screening program was 54.4 ± 9.3 years. According to the CVD charts published by the WHO, about 48% (n = 17,282) of the study population had a low 10-year CVD risk (<10%), 41% (n = 14,554) had a mild risk (10-20%), 12% (n = 3,502) had a moderate risk (20-30%), and 1% (n = 431) had a high risk (>30%). CONCLUSION: More than half of the screening program participants were identified as having a 10-year CVD risk greater than 10%. Effective intervention focusing on the male population living in urban areas, and target on major risk factors like hypertension, smoking and diabetes can be strategic approach to reducing the CVD risk in Mongolia.Scopus© Citations 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Antibody responses to mRNA versus non-mRNA COVID vaccines among the Mongolian population(Elsevier BV, 2023-09); Scopus© Citations 4 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, One-year antibody kinetics and effectiveness of a BNT162b2 booster after four primary COVID-19 vaccination regimens in Mongolia(2026-09) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Molecular epidemiology of SARS-CoV-2 in Mongolia, first experience with nanopore sequencing in lower- and middle-income countries setting(Wiley, 2023-12); ; ; ; Burged, NatsagdorjBACKGROUND: Coronavirus disease (COVID-19) has had a significant impact globally, and extensive genomic research has been conducted on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage patterns and its variants. Mongolia's effective response resulted in low prevalence until vaccinations became available. However, due to the lack of systematically collected data and absence of whole genome sequencing capabilities, we conducted a two-stepped, nationally representative molecular epidemiologic study of SARS-CoV-2 in Mongolia for 2020 and 2021. METHODS: We used retrospective analysis of stored biological samples from November 2020 to October 2021 and a variant-specific real-time reverse transcription polymerase chain reaction (RT-PCR) test to detect SARS-CoV-2 variants, followed by whole genome sequencing by Nanopore technology. Samples were retrieved from different sites and stored at -70°C deep freezer, and tests were performed on samples with cycle threshold <30. RESULTS: Out of 4879 nucleic acid tests, 799 whole genome sequencing had been carried out. Among the stored samples of earlier local transmission, we found the 20B (B.1.1.46) variant predominated in the earlier local transmission period. A slower introduction and circulation of alpha and delta variants were observed compared to global dynamics in 2020 and 2021. Beta or Gamma variants were not detected between November 2020 and September 2021 in Mongolia. CONCLUSIONS: SARS-CoV-2 variants of concerns including alpha and delta were delayed in circulation potentially due to public health stringencies in Mongolia. We are sharing our initial experience with whole genome sequencing of SARS-CoV-2 from Mongolia, where sequencing data is sparse.Scopus© Citations 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Correction: Distribution of 10-year cardiovascular disease risk levels in Mongolia: results from nation-wide health screening program[This corrects the article DOI: 10.3389/fpubh.2025.1412262.]. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Examining Age-Adjusted Associations between BMI and Comorbidities in Mongolia: Cross-Sectional Prevalence(2024-06); ; ; Scopus© Citations 9